version 12 1 copyright 1985 2011 Search Results


enamine 120  (Enamine Ltd)
90
Enamine Ltd enamine 120
Enamine 120, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/10__1016_slash_j__jfluchem__2020__109639-365-0-0?v=Enamine+Ltd
Average 90 stars, based on 1 article reviews
enamine 120 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
stata version 12 1  (STATA Corporation)
99
STATA Corporation stata version 12 1
Stata Version 12 1, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/pm27883269-113-5-5?v=STATA+Corporation
Average 99 stars, based on 1 article reviews
stata version 12 1 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
antibodies against pgc1c  (Cayman Chemical)
90
Cayman Chemical antibodies against pgc1c
Antibodies Against Pgc1c, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/us11116784-756-0-3?v=Cayman+Chemical
Average 90 stars, based on 1 article reviews
antibodies against pgc1c - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
schnuck ivdk  (Schnuck Markets)
90
Schnuck Markets schnuck ivdk
Schnuck Ivdk, supplied by Schnuck Markets, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/10__1097_slash_der__0000000000000429-294-94-93?v=Schnuck+Markets
Average 90 stars, based on 1 article reviews
schnuck ivdk - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
micro regions  (Apodi Inc)
90
Apodi Inc micro regions
Micro Regions, supplied by Apodi Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/pm30659709-517-0-75?v=Apodi+Inc
Average 90 stars, based on 1 article reviews
micro regions - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cd68 (+)  (Zhongshan Bio Tech Co)
90
Zhongshan Bio Tech Co cd68 (+)
Cd68 (+), supplied by Zhongshan Bio Tech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/10__1097_slash_md__0000000000021999-107-23-27?v=Zhongshan+Bio+Tech+Co
Average 90 stars, based on 1 article reviews
cd68 (+) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
71 ihc cd68 cd163 cd68 boster  (Boster Bio)
96
Boster Bio 71 ihc cd68 cd163 cd68 boster
Figure 2. Forest plots showing hazard ratios (HRs) and 95% CIs for (A) density of <t>CD68+</t> TAMs in IT and OS; (B) density of <t>CD68+</t> TAMs in IT and DFS; (C) density of <t>CD163+</t> M2-like TAMs in IT and OS; and (D) density of <t>CD163+</t> M2-like TAMs in IT and DFS. CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs=tumor-associated macrophages.
71 Ihc Cd68 Cd163 Cd68 Boster, supplied by Boster Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+12+1+copyright+1985+2011/10__1097_slash_md__0000000000021999-107-118-125?v=Boster+Bio
Average 96 stars, based on 1 article reviews
71 ihc cd68 cd163 cd68 boster - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Forest plots showing hazard ratios (HRs) and 95% CIs for (A) density of CD68+ TAMs in IT and OS; (B) density of CD68+ TAMs in IT and DFS; (C) density of CD163+ M2-like TAMs in IT and OS; and (D) density of CD163+ M2-like TAMs in IT and DFS. CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs=tumor-associated macrophages.

Journal: Medicine

Article Title: Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal carcinoma

doi: 10.1097/md.0000000000021999

Figure Lengend Snippet: Figure 2. Forest plots showing hazard ratios (HRs) and 95% CIs for (A) density of CD68+ TAMs in IT and OS; (B) density of CD68+ TAMs in IT and DFS; (C) density of CD163+ M2-like TAMs in IT and OS; and (D) density of CD163+ M2-like TAMs in IT and DFS. CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs=tumor-associated macrophages.

Article Snippet: Author Year Country Sample size Sex (M/F) Study duration Age mean (range) Detection method Marker Antibody He 1999 China 43 33/10 1985–1990 46.8 (22–71) IHC CD68 (+) Zhongshan Bio-tech Co Ltd, China Cai 2016 China 557 418/139 2001–2003 46 (19–78) IHC CD68 (+) NR Huang (a) 2017 China 580 446/134 2009–2011 45 (24–77) IHC CD68 (+) CD68 (+)CCL18 (+) CD68: Cat No. sc7083 Santa Cruz, USA CCL18: Cat No. MAB394 R&D Systems, USA Huang (b) 2017 China 110 87/23 2008–2012 NR IHC CD163 (+) CD163: Mouse, Abcam, USA Xia 2017 China 107 NR 2009–2010 24–77 IHC CD163 (+) CD206 (+) CD163: Mouse, Zhongshan Golden Bridge, Beijing, China CD206: Mouse, Abcam, USA Yu 2018 China 152 121/31 1999–2000 48 (18–71) IHC CD68 (+) CD163 (+) CD68: Boster, Wuhan, China CD163: Zhongshan Golden Bridge, China Stage Treatment Tissue detection Cut-off value Follow-up (month) Study design Survival analysis NOS score III CCRT IT >10 cells/field (200X) 60–120 Retrospective OS 6 I–IV Mixed IT, TS ROC curve 2–114 Retrospective OS, DFS 7 I–IV Mixed IT >22 cells/field (400 ) 43 (8–58) Retrospective OS, DFS 7 I–IV Mixed IT, TS Median value 53 (10–86) Retrospective OS, DFS 8 I–II Surgery IT >20 cells/field (400 ) To Dec 2015 Retrospective OS, DFS 7 I–IV RT IT >Score 2 130 (5–144) Retrospective OS, DFS 7 CCRT= concurrent chemoradiothrapy; DFS=disease-free survival; F= female; IHC= immunohistochemistry; IT= intratumor; M=male; NOS=Newcastle-Ottawa Scale; NR=not reported; OS= overall survival; RT= radiotherapy; TS= tumor stroma.

Techniques:

Figure 3. Sensitivity analysis for the (A) density of CD68+ TAMs in IT and OS; (B) density of CD68+ TAMs in IT and DFS; (C) density of CD163+ M2-like TAMs in IT and OS; and (D) density of CD163+ M2-like TAMs in IT and DFS. CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs= tumor-associated macrophages.

Journal: Medicine

Article Title: Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal carcinoma

doi: 10.1097/md.0000000000021999

Figure Lengend Snippet: Figure 3. Sensitivity analysis for the (A) density of CD68+ TAMs in IT and OS; (B) density of CD68+ TAMs in IT and DFS; (C) density of CD163+ M2-like TAMs in IT and OS; and (D) density of CD163+ M2-like TAMs in IT and DFS. CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs= tumor-associated macrophages.

Article Snippet: Author Year Country Sample size Sex (M/F) Study duration Age mean (range) Detection method Marker Antibody He 1999 China 43 33/10 1985–1990 46.8 (22–71) IHC CD68 (+) Zhongshan Bio-tech Co Ltd, China Cai 2016 China 557 418/139 2001–2003 46 (19–78) IHC CD68 (+) NR Huang (a) 2017 China 580 446/134 2009–2011 45 (24–77) IHC CD68 (+) CD68 (+)CCL18 (+) CD68: Cat No. sc7083 Santa Cruz, USA CCL18: Cat No. MAB394 R&D Systems, USA Huang (b) 2017 China 110 87/23 2008–2012 NR IHC CD163 (+) CD163: Mouse, Abcam, USA Xia 2017 China 107 NR 2009–2010 24–77 IHC CD163 (+) CD206 (+) CD163: Mouse, Zhongshan Golden Bridge, Beijing, China CD206: Mouse, Abcam, USA Yu 2018 China 152 121/31 1999–2000 48 (18–71) IHC CD68 (+) CD163 (+) CD68: Boster, Wuhan, China CD163: Zhongshan Golden Bridge, China Stage Treatment Tissue detection Cut-off value Follow-up (month) Study design Survival analysis NOS score III CCRT IT >10 cells/field (200X) 60–120 Retrospective OS 6 I–IV Mixed IT, TS ROC curve 2–114 Retrospective OS, DFS 7 I–IV Mixed IT >22 cells/field (400 ) 43 (8–58) Retrospective OS, DFS 7 I–IV Mixed IT, TS Median value 53 (10–86) Retrospective OS, DFS 8 I–II Surgery IT >20 cells/field (400 ) To Dec 2015 Retrospective OS, DFS 7 I–IV RT IT >Score 2 130 (5–144) Retrospective OS, DFS 7 CCRT= concurrent chemoradiothrapy; DFS=disease-free survival; F= female; IHC= immunohistochemistry; IT= intratumor; M=male; NOS=Newcastle-Ottawa Scale; NR=not reported; OS= overall survival; RT= radiotherapy; TS= tumor stroma.

Techniques:

Figure 4. Publication bias examined by Begg plot test for (A) density of CD68+ TAMs in IT and OS (P=.734); (B) density of CD68+ TAMs in IT and DFS (P=1); (C) density of CD163+ M2-like TAMs in IT and OS (P=.602); and density of CD163+ M2-like TAMs in IT and DFS (P=1). CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs=tumor-associated macrophages.

Journal: Medicine

Article Title: Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal carcinoma

doi: 10.1097/md.0000000000021999

Figure Lengend Snippet: Figure 4. Publication bias examined by Begg plot test for (A) density of CD68+ TAMs in IT and OS (P=.734); (B) density of CD68+ TAMs in IT and DFS (P=1); (C) density of CD163+ M2-like TAMs in IT and OS (P=.602); and density of CD163+ M2-like TAMs in IT and DFS (P=1). CI=confidence interval; DFS=disease-free survival; IT=intratumor; OS=overall survival; TAMs=tumor-associated macrophages.

Article Snippet: Author Year Country Sample size Sex (M/F) Study duration Age mean (range) Detection method Marker Antibody He 1999 China 43 33/10 1985–1990 46.8 (22–71) IHC CD68 (+) Zhongshan Bio-tech Co Ltd, China Cai 2016 China 557 418/139 2001–2003 46 (19–78) IHC CD68 (+) NR Huang (a) 2017 China 580 446/134 2009–2011 45 (24–77) IHC CD68 (+) CD68 (+)CCL18 (+) CD68: Cat No. sc7083 Santa Cruz, USA CCL18: Cat No. MAB394 R&D Systems, USA Huang (b) 2017 China 110 87/23 2008–2012 NR IHC CD163 (+) CD163: Mouse, Abcam, USA Xia 2017 China 107 NR 2009–2010 24–77 IHC CD163 (+) CD206 (+) CD163: Mouse, Zhongshan Golden Bridge, Beijing, China CD206: Mouse, Abcam, USA Yu 2018 China 152 121/31 1999–2000 48 (18–71) IHC CD68 (+) CD163 (+) CD68: Boster, Wuhan, China CD163: Zhongshan Golden Bridge, China Stage Treatment Tissue detection Cut-off value Follow-up (month) Study design Survival analysis NOS score III CCRT IT >10 cells/field (200X) 60–120 Retrospective OS 6 I–IV Mixed IT, TS ROC curve 2–114 Retrospective OS, DFS 7 I–IV Mixed IT >22 cells/field (400 ) 43 (8–58) Retrospective OS, DFS 7 I–IV Mixed IT, TS Median value 53 (10–86) Retrospective OS, DFS 8 I–II Surgery IT >20 cells/field (400 ) To Dec 2015 Retrospective OS, DFS 7 I–IV RT IT >Score 2 130 (5–144) Retrospective OS, DFS 7 CCRT= concurrent chemoradiothrapy; DFS=disease-free survival; F= female; IHC= immunohistochemistry; IT= intratumor; M=male; NOS=Newcastle-Ottawa Scale; NR=not reported; OS= overall survival; RT= radiotherapy; TS= tumor stroma.

Techniques: